Cargando…
Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
BACKGROUND: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody...
Autores principales: | Payandeh, Zahra, Rajabibazl, Masoumeh, Mortazavi, Yousef, Rahimpour, Azam, Taromchi, Amir Hossein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pasteur Institute
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889503/ https://www.ncbi.nlm.nih.gov/pubmed/28992681 http://dx.doi.org/10.22034/ibj.22.3.180 |
Ejemplares similares
-
Induction of Immunogenic Response in BALB/c Mice by Live and Killed Form of Recombinant Lactococcus lactis Displaying EG95 of Echinococcus granulosus
por: Ebrahimzadeh, Fatemeh, et al.
Publicado: (2021) -
Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010) -
In silico Evaluation of PLAC1-fliC As a Chimeric Vaccine against Breast Cancer
por: Taheri-Anganeh, Mortaza, et al.
Publicado: (2020) -
Quantitative Proteomic Analysis of Cellular Responses to a Designed Amino Acid Feed in a Monoclonal Antibody Producing Chinese Hamster Ovary Cell Line
por: Torkashvand, Fatemeh, et al.
Publicado: (2018) -
Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor
por: Hajihassan, Zahra, et al.
Publicado: (2023)